Pharmaceuticals revenue for obstructive airway diseases in Norway 2007-2020
This statistic shows the revenue from pharmaceuticals for obstructive airway disease - a group of lung diseases including, asthma, bronchitis, and COPD, and others - in Norway from 2007 to 2020. Revenues fluctuated over the years, and reached its peak in 2020, when it stood at 1.35 billion Norwegian kroner.